Cancer treatment and survivorship statistics, 2014

The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment. In order for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborated to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) program registries. In addition, current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SEER‐Medicare linked databases; treatment‐related side effects are also briefly described. Nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014; by January 1, 2024, that number will increase to nearly 19 million. The 3 most common prevalent cancers among males are prostate cancer (43%), colorectal cancer (9%), and melanoma (8%), and those among females are cancers of the breast (41%), uterine corpus (8%), and colon and rectum (8%). The age distribution of survivors varies substantially by cancer type. For example, the majority of prostate cancer survivors (62%) are aged 70 years or older, whereas less than one‐third (32%) of melanoma survivors are in this older age group. It is important for clinicians to understand the unique medical and psychosocial needs of cancer survivors and to proactively assess and manage these issues. There are a growing number of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship. CA Cancer J Clin 2014;64:252–271. © 2014 American Cancer Society.

[1]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[2]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.

[3]  P. Stephens,et al.  Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary , 2013, Clinical Cancer Research.

[4]  C. Ko,et al.  Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Warde,et al.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Edge,et al.  Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[8]  P. Jain,et al.  Richter's Transformation in Chronic Lymphocytic Leukemia Richter's Transformation in Chronic Lymphocytic Leukemia , 2022 .

[9]  David Botstein,et al.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Marilyn Stovall,et al.  Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Yamada,et al.  Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.

[12]  J. Hoffman-Censits,et al.  Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[13]  Julia H. Rowland,et al.  Mental and Physical Health–Related Quality of Life among U.S. Cancer Survivors: Population Estimates from the 2010 National Health Interview Survey , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[14]  G. Andriole Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .

[15]  K. Dookeran,et al.  Racial and Ethnic Differences in Breast Cancer Survival: How Much Is Explained by Screening, Tumor Severity, Biology, Treatment, Comorbidities, and Demographics? , 2008 .

[16]  H. Brenner,et al.  Quality of life among long-term (≥5 years) colorectal cancer survivors--systematic review. , 2010, European journal of cancer.

[17]  Rebecca Smith-Bindman,et al.  Racial and ethnic differences in breast cancer survival , 2008, Cancer.

[18]  P. Conte,et al.  Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective , 2007, The breast journal.

[19]  Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors , 2013, Breast Cancer Research.

[20]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[21]  G. Armstrong,et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.

[22]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[23]  H. Kehlet,et al.  Prevalence of and factors associated with persistent pain following breast cancer surgery. , 2009, JAMA.

[24]  R. Jagsi,et al.  Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Gustafsson,et al.  Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden , 2006, Cancer.

[26]  L. Strobbe,et al.  Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. , 2008, The journal of pain : official journal of the American Pain Society.

[27]  A. D'Amico,et al.  Androgen‐Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology , 2010, CA: a cancer journal for clinicians.

[28]  P. Warde,et al.  Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy , 2013, BJU international.

[29]  H. Kehlet,et al.  Persistent postsurgical pain: risk factors and prevention , 2006, The Lancet.

[30]  C. O’Malley,et al.  Diabetes in elderly patients with breast cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Santoro,et al.  Central role of RET in thyroid cancer. , 2013, Cold Spring Harbor perspectives in biology.

[32]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.

[33]  M. Aghili,et al.  Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer , 2010, Asia-Pacific journal of clinical oncology.

[34]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[35]  Prokar Dasgupta,et al.  Recent advances in the diagnosis and treatment of bladder cancer , 2013, BMC Medicine.

[36]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[37]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[38]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2010, Journal of the National Cancer Institute.

[39]  K. McGuire,et al.  Are Mastectomies on the Rise? A 13-Year Trend Analysis of the Selection of Mastectomy Versus Breast Conservation Therapy in 5865 Patients , 2009, Annals of Surgical Oncology.

[40]  N. Parr,et al.  Long‐term changes in bone mineral density and predicted fracture risk in patients receiving androgen‐deprivation therapy for prostate cancer, with stratification of treatment based on presenting values , 2009, BJU international.

[41]  S. Sindrup,et al.  The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer , 2008, British Journal of Cancer.

[42]  S. Bhatia Disparities in cancer outcomes: Lessons learned from children with cancer , 2011, Pediatric blood & cancer.

[43]  H. Sasaki,et al.  Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma , 2009, BMC Cancer.

[44]  J. Griggs,et al.  Use of radioactive iodine for thyroid cancer. , 2011, JAMA.

[45]  R. Saskin,et al.  Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. , 2014, The Lancet. Oncology.

[46]  Xianglin L. Du,et al.  Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node‐positive, operable breast cancer , 2009, Cancer.

[47]  G. Colditz,et al.  Online Continuing Education Activity Article Title: American Cancer Society Lung Cancer Screening Guidelines Continuing Medical Education Accreditation and Designation Statement: Continuing Nursing Education Accreditation and Designation Statement: Educational Objectives: Activity Disclosures Acs Co , 2022 .

[48]  F. Rosendaal,et al.  Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors , 2013, British Journal of Cancer.

[49]  D. Hughes,et al.  Weight Lifting for Women at Risk for Breast Cancer–Related Lymphedema: A Randomized Trial , 2011 .

[50]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[51]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[52]  A. Bleyer Young Adult Oncology: The Patients and Their Survival Challenges , 2007, CA: a cancer journal for clinicians.

[53]  M. Goldfarb,et al.  Well‐differentiated thyroid carcinoma: The role of post‐operative radioactive iodine administration , 2013, Journal of surgical oncology.

[54]  L. Koniaris,et al.  Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. , 2008, The Journal of urology.

[55]  J. Mohler The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[56]  C. Pui,et al.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia. , 2008, The Lancet. Oncology.

[57]  Steve Scoppa,et al.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2007, Cancer Epidemiology Biomarkers & Prevention.

[58]  B. Coiffier,et al.  State-of-the-art therapeutics: diffuse large B-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Polednak Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. , 2008, Cancer detection and prevention.

[60]  B. Newman,et al.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. , 2013, The Lancet. Oncology.

[61]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[62]  E. Feuer,et al.  Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020 , 2006, Cancer Causes & Control.

[63]  Peter Baade,et al.  A systematic review of the impact of stigma and nihilism on lung cancer outcomes , 2012, BMC Cancer.

[64]  C. Audette,et al.  The sexual health of women after gynecologic malignancy. , 2010, Journal of midwifery & women's health.

[65]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[66]  R. Huddart,et al.  Comment on ‘Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors' , 2013, British Journal of Cancer.

[67]  F. Behm,et al.  Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.

[68]  Ahmedin Jemal,et al.  Childhood and adolescent cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[69]  E. de Azambuja,et al.  Improving quality of life after breast cancer: dealing with symptoms. , 2011, Maturitas.

[70]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[71]  P. Ganz,et al.  Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[72]  F. Frasca,et al.  Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors , 2013, Journal of cancer epidemiology.

[73]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[74]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[75]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[76]  P. Mauch,et al.  Nodular lymphocyte-predominant hodgkin lymphoma. , 2007, Seminars in radiation oncology.

[77]  J. Zajac,et al.  Hematological changes during androgen deprivation therapy. , 2012, Asian journal of andrology.

[78]  Andrew Ma,et al.  Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.

[79]  M. Brennan,et al.  Uptake and predictors of post-mastectomy reconstruction in women with breast malignancy--systematic review. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[80]  Karen R. Sepucha,et al.  Are Patients Making High-Quality Decisions about Breast Reconstruction after Mastectomy? [Outcomes Article] , 2011, Plastic and reconstructive surgery.

[81]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[82]  M. Graefen,et al.  Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[83]  A. Zietman,et al.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. , 2013, The Lancet. Oncology.

[84]  A. Bleyer,et al.  The adolescence of young adult oncology. , 2009, Seminars in oncology.

[85]  S. Groshen,et al.  Long‐term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy , 2011, BJU international.

[86]  D. Rose,et al.  The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. , 2009, Journal of women's health.

[87]  R. Capocaccia,et al.  Estimation and projections of cancer prevalence from cancer registry data , 2002, Statistics in medicine.

[88]  Stacey A. Kenfield,et al.  Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  L. Harlan,et al.  Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[91]  J. Cayuela,et al.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  E. Hill,et al.  Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. , 2012, Blood.

[93]  P. Johnstone,et al.  Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment , 2009, CA: a cancer journal for clinicians.

[94]  H. Kantarjian,et al.  The biology and therapy of adult acute lymphoblastic leukemia , 2003, Cancer.

[95]  S. L. Stewart,et al.  Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. , 2011, Journal of the American Academy of Dermatology.

[96]  Gretchen L. Gierach,et al.  Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. , 2013, Journal of the National Cancer Institute.

[97]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[98]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[99]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[100]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[101]  Claire Schwab,et al.  Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.

[102]  M. Proschan,et al.  Randomized Trials of Breast-Conserving Therapy Versus Mastectomy for Primary Breast Cancer: A Pooled Analysis of Updated Results , 2005, American journal of clinical oncology.